<p>隨着美國股市持續攀升，納斯達克和標準普爾 500 等指數創下新高，投資者正在探索市場不同領域的各種機會。便士股票，這個可能顯得過時但仍然重要的術語，代表着較小或不太成熟的公司，可能提供潛在的價值。通過關注那些財務穩健且具有增長潛力的公司，投資者可能會在這些鮮為人知的股票中發現有前景的機會。</p>
<h3>美國十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.04</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.97</td>
<td>$705.24M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.16</td>
<td>$201.8M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Performance Shipping (PSHG)</td>
<td>$1.90</td>
<td>$23.5M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.98</td>
<td>$636.96M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.97</td>
<td>$7.21M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.81</td>
<td>$88.82M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Universal Safety Products (UUU)</td>
<td>$4.99</td>
<td>$10.96M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Resources Connection (RGP)</td>
<td>$4.92</td>
<td>$165.51M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國便士股票篩選器中的 362 只股票的完整列表。</p>
<p>在這裏，我們突出顯示了我們篩選器中首選股票的一個子集。</p>
<h2>Rapid Micro Biosystems (RPID)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Rapid Micro Biosystems, Inc. 是一家生命科學技術公司，提供用於檢測製藥、醫療設備和個人護理產品製造中微生物污染的產品，市值為 1.6756 億美元，覆蓋多個國際市場。</p>
<p><strong>運營：</strong> 該公司主要通過系統及相關的 LIMS 連接軟件、耗材和服務產生收入，總計 3029 萬美元。</p>
<p><strong>市值：</strong> 1.6756 億美元</p>
<p>Rapid Micro Biosystems, Inc. 以 1.6756 億美元的市值在便士股票的挑戰性環境中，專注於收入增長和財務穩定。儘管公司處於虧損狀態，股本回報率為負，但其收入持續增長，2025 年上半年報告收入為 1447 萬美元，而 2024 年為 1223 萬美元。公司無債務，並且最近獲得了 4500 萬美元的貸款，以支持其全球擴張和提高製造效率。管理團隊經驗豐富，短期負債由價值 6010 萬美元的資產充分覆蓋。</p>
<ul>
<li>點擊探索我們在 Rapid Micro Biosystems 財務健康報告中的詳細發現。</li>
<li>通過訪問我們的收益增長報告評估 Rapid Micro Biosystems 的前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8cf9af1a-87ce-436e-aae4-9eeaabf35533/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8cf9af1a-87ce-436e-aae4-9eeaabf35533/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 10 月的 RPID 債務與股本歷史及分析</p>
<h2>Nuvation Bio (NUVB)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Nuvation Bio Inc. 是一家臨牀階段的生物製藥公司，開發用於腫瘤學的治療候選藥物，市值約為 12.7 億美元。</p>
<p><strong>運營：</strong> Nuvation Bio 的收入主要來自其腫瘤學開發活動，總計 1436 萬美元。</p>
<p><strong>市值：</strong> 12.7 億美元</p>
<p>Nuvation Bio Inc. 是一家市值為 12.7 億美元的臨牀階段生物製藥公司，正在通過推進其腫瘤學管線，特別是 IBTROZI™（taletrectinib），在便士股票市場中尋求發展。最近獲得日本 MHLW 和美國 FDA 的批准，突顯其在治療 ROS1 陽性非小細胞肺癌方面的潛力。儘管公司處於虧損狀態，2025 年上半年報告收入為 792 萬美元，且流動性強，短期資產顯著超過負債。公司現金多於債務，但面臨高波動性和董事會經驗不足等挑戰。</p>
<ul>
<li>解鎖我們對 Nuvation Bio 股票分析的全面見解，查看此財務健康報告。</li>
<li>通過我們的詳細增長報告評估 Nuvation Bio 未來的收益預期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d2ddebb-038e-4cd4-82b7-a76373f619a3/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d2ddebb-038e-4cd4-82b7-a76373f619a3/chart/financial-position-analysis"/></p>
<p>截至 2025 年 10 月的 NUVB 財務狀況分析</p>
<h2>Waterdrop (WDH)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Waterdrop Inc. 在中國作為在線保險經紀公司運營，連接用户與保險產品，市值約為 7.0524 億美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自其保險業務，產生了 28.78 億人民幣，此外還有 1536.8 萬人民幣來自眾籌活動。</p>
<p><strong>市值：</strong> 7.0524 億美元</p>
<p>Waterdrop Inc. 在便士股票領域表現出強勁的財務表現，市值約為 7.0524 億美元。公司報告了顯著的收益增長，2025 年第二季度淨收入上升至 1.4016 億人民幣，較去年同期的 8829 萬人民幣有所增加。其短期資產（40 億人民幣）輕鬆覆蓋負債，並且通過現金多於債務保持強勁的流動性。儘管交易價格低於其估計的公允價值，並且擁有高質量的收益，Waterdrop 的股本回報率仍然較低，為 8.6%。最近的戰略舉措包括價值 5000 萬美元的股票回購計劃和增強股東價值的股息確認。</p>
<ul>
<li>在我們的財務健康報告中更深入地瞭解 Waterdrop 的潛力。</li>
<li>檢查 Waterdrop 的收益增長報告，以瞭解分析師對其表現的預期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5ec70547-526e-42d6-ac6d-8a4bcdf65c9f/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5ec70547-526e-42d6-ac6d-8a4bcdf65c9f/chart/financial-position-analysis"/></p>
<p>WDH 財務狀況分析截至 2025 年 10 月</p>
<h2>利用機會</h2>
<ul>
<li>通過在這裏使用我們的篩選器，深入瞭解所有 362 只美國便士股票。</li>
<li>尋找新的視角？癌症的終結？這 28 只新興 AI 股票正在開發技術，以便早期識別改變生命的疾病，如癌症和阿爾茨海默病。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

水滴

RPID

NUVB

<p>隨着美國股市的上漲，投資者開始關注低價股的潛在價值。值得一提的是 Rapid Micro Biosystems（RPID），這是一家市值為 1.6756 億美元的生命科學技術公司，專注於微生物污染檢測。儘管尚未盈利，但該公司報告了收入增長，並獲得了 4500 萬美元的貸款用於擴張。Nuvation Bio（NUVB）是一家市值為 12.7 億美元的生物製藥公司，正在推進其腫瘤學產品線。水滴（WDH）是一家中國的在線保險經紀公司，顯示出強勁的盈利增長，並保持良好的流動性</p>

<p>As the U.S. stock market continues to climb, with indices like the Nasdaq and S&amp;P 500 reaching new highs, investors are exploring various opportunities in different segments of the market. Penny stocks, a term that may seem outdated yet remains significant, represent smaller or less-established companies that can offer potential value. By focusing on those with solid financials and growth potential, investors might uncover promising opportunities among these lesser-known stocks.</p>
<div class="lb-trans"><p>隨着美國股市持續攀升，納斯達克和標準普爾 500 等指數創下新高，投資者正在探索市場不同領域的各種機會。便士股票，這個可能顯得過時但仍然重要的術語，代表着較小或不太成熟的公司，可能提供潛在的價值。通過關注那些財務穩健且具有增長潛力的公司，投資者可能會在這些鮮為人知的股票中發現有前景的機會。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美國十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.04</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.97</td>
<td>$705.24M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.16</td>
<td>$201.8M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Performance Shipping (PSHG)</td>
<td>$1.90</td>
<td>$23.5M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.98</td>
<td>$636.96M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.97</td>
<td>$7.21M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.81</td>
<td>$88.82M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Universal Safety Products (UUU)</td>
<td>$4.99</td>
<td>$10.96M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Resources Connection (RGP)</td>
<td>$4.92</td>
<td>$165.51M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.04</td>
<td>$437.18M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.97</td>
<td>$705.24M</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$1.16</td>
<td>$201.8M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Performance Shipping (PSHG)</td>
<td>$1.90</td>
<td>$23.5M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.98</td>
<td>$636.96M</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.97</td>
<td>$7.21M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.81</td>
<td>$88.82M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Universal Safety Products (UUU)</td>
<td>$4.99</td>
<td>$10.96M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Resources Connection (RGP)</td>
<td>$4.92</td>
<td>$165.51M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 362 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國便士股票篩選器中的 362 只股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在這裏，我們突出顯示了我們篩選器中首選股票的一個子集。</p>
</div><h2>Rapid Micro Biosystems (RPID)</h2>
<div class="lb-trans"><h2>Rapid Micro Biosystems (RPID)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Rapid Micro Biosystems, Inc. is a life sciences technology company that offers products for detecting microbial contamination in the manufacturing of pharmaceuticals, medical devices, and personal care products across various international markets, with a market cap of $167.56 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Rapid Micro Biosystems, Inc. 是一家生命科學技術公司，提供用於檢測製藥、醫療設備和個人護理產品製造中微生物污染的產品，市值為 1.6756 億美元，覆蓋多個國際市場。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from Systems and Related LIMS Connection Software, Consumables, and Services, totaling $30.29 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過系統及相關的 LIMS 連接軟件、耗材和服務產生收入，總計 3029 萬美元。</p>
</div><p><strong>Market Cap:</strong> $167.56M</p>
<div class="lb-trans"><p><strong>市值：</strong> 1.6756 億美元</p>
</div><p>Rapid Micro Biosystems, Inc., with a market cap of US$167.56 million, is navigating the challenging landscape of penny stocks by focusing on revenue growth and financial stability. Despite being unprofitable with a negative return on equity, the company has shown consistent revenue increases, reporting US$14.47 million for the first half of 2025 compared to US$12.23 million in 2024. It remains debt-free and has recently secured a US$45 million loan facility to support its global expansion efforts and enhance manufacturing efficiencies. The management team is experienced, and short-term liabilities are well-covered by assets worth US$60.1 million.</p>
<div class="lb-trans"><p>Rapid Micro Biosystems, Inc. 以 1.6756 億美元的市值在便士股票的挑戰性環境中，專注於收入增長和財務穩定。儘管公司處於虧損狀態，股本回報率為負，但其收入持續增長，2025 年上半年報告收入為 1447 萬美元，而 2024 年為 1223 萬美元。公司無債務，並且最近獲得了 4500 萬美元的貸款，以支持其全球擴張和提高製造效率。管理團隊經驗豐富，短期負債由價值 6010 萬美元的資產充分覆蓋。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Rapid Micro Biosystems' financial health report.</li>
<li>Evaluate Rapid Micro Biosystems' prospects by accessing our earnings growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 Rapid Micro Biosystems 財務健康報告中的詳細發現。</li>
<li>通過訪問我們的收益增長報告評估 Rapid Micro Biosystems 的前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8cf9af1a-87ce-436e-aae4-9eeaabf35533/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/8cf9af1a-87ce-436e-aae4-9eeaabf35533/chart/debt-equity-history-analysis"/></p>
<p>RPID Debt to Equity History and Analysis as at Oct 2025</p>
<div class="lb-trans"><p>截至 2025 年 10 月的 RPID 債務與股本歷史及分析</p>
</div><h2>Nuvation Bio (NUVB)</h2>
<div class="lb-trans"><h2>Nuvation Bio (NUVB)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Nuvation Bio Inc. is a clinical-stage biopharmaceutical company that develops therapeutic candidates for oncology, with a market cap of approximately $1.27 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Nuvation Bio Inc. 是一家臨牀階段的生物製藥公司，開發用於腫瘤學的治療候選藥物，市值約為 12.7 億美元。</p>
</div><p><strong>Operations:</strong> Nuvation Bio generates revenue from its oncology development activities, totaling $14.36 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> Nuvation Bio 的收入主要來自其腫瘤學開發活動，總計 1436 萬美元。</p>
</div><p><strong>Market Cap:</strong> $1.27B</p>
<div class="lb-trans"><p><strong>市值：</strong> 12.7 億美元</p>
</div><p>Nuvation Bio Inc., a clinical-stage biopharmaceutical company with a market cap of US$1.27 billion, is navigating the penny stock landscape by advancing its oncology pipeline, particularly with IBTROZI™ (taletrectinib). Recent approvals from Japan's MHLW and the U.S. FDA highlight its potential in treating ROS1-positive non-small cell lung cancer. Despite being unprofitable, Nuvation Bio reported US$7.92 million in revenue for the first half of 2025 and maintains strong liquidity with short-term assets exceeding liabilities significantly. The company has more cash than debt but faces challenges like high volatility and an inexperienced board of directors.</p>
<div class="lb-trans"><p>Nuvation Bio Inc. 是一家市值為 12.7 億美元的臨牀階段生物製藥公司，正在通過推進其腫瘤學管線，特別是 IBTROZI™（taletrectinib），在便士股票市場中尋求發展。最近獲得日本 MHLW 和美國 FDA 的批准，突顯其在治療 ROS1 陽性非小細胞肺癌方面的潛力。儘管公司處於虧損狀態，2025 年上半年報告收入為 792 萬美元，且流動性強，短期資產顯著超過負債。公司現金多於債務，但面臨高波動性和董事會經驗不足等挑戰。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Nuvation Bio stock in this financial health report.</li>
<li>Assess Nuvation Bio's future earnings estimates with our detailed growth reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對 Nuvation Bio 股票分析的全面見解，查看此財務健康報告。</li>
<li>通過我們的詳細增長報告評估 Nuvation Bio 未來的收益預期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d2ddebb-038e-4cd4-82b7-a76373f619a3/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/1d2ddebb-038e-4cd4-82b7-a76373f619a3/chart/financial-position-analysis"/></p>
<p>NUVB Financial Position Analysis as at Oct 2025</p>
<div class="lb-trans"><p>截至 2025 年 10 月的 NUVB 財務狀況分析</p>
</div><h2>Waterdrop (WDH)</h2>
<div class="lb-trans"><h2>Waterdrop (WDH)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Waterdrop Inc. operates as an online insurance brokerage in China, connecting users with insurance products, and has a market cap of approximately $705.24 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Waterdrop Inc. 在中國作為在線保險經紀公司運營，連接用户與保險產品，市值約為 7.0524 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its insurance segment, which generated CN¥2.78 billion, complemented by CN¥153.68 million from crowd funding activities.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其保險業務，產生了 28.78 億人民幣，此外還有 1536.8 萬人民幣來自眾籌活動。</p>
</div><p><strong>Market Cap:</strong> $705.24M</p>
<div class="lb-trans"><p><strong>市值：</strong> 7.0524 億美元</p>
</div><p>Waterdrop Inc., with a market cap of approximately US$705.24 million, has shown robust financial performance in the penny stock arena. The company reported significant earnings growth, with net income rising to CN¥140.16 million for Q2 2025, up from CN¥88.29 million a year ago. Its short-term assets (CN¥4 billion) comfortably cover liabilities, and it maintains strong liquidity by having more cash than debt. Despite trading below its estimated fair value and boasting high-quality earnings, Waterdrop's return on equity remains low at 8.6%. Recent strategic moves include a share repurchase program worth US$50 million and dividend affirmations enhancing shareholder value.</p>
<div class="lb-trans"><p>Waterdrop Inc. 在便士股票領域表現出強勁的財務表現，市值約為 7.0524 億美元。公司報告了顯著的收益增長，2025 年第二季度淨收入上升至 1.4016 億人民幣，較去年同期的 8829 萬人民幣有所增加。其短期資產（40 億人民幣）輕鬆覆蓋負債，並且通過現金多於債務保持強勁的流動性。儘管交易價格低於其估計的公允價值，並且擁有高質量的收益，Waterdrop 的股本回報率仍然較低，為 8.6%。最近的戰略舉措包括價值 5000 萬美元的股票回購計劃和增強股東價值的股息確認。</p>
</div><ul>
<li>Take a closer look at Waterdrop's potential here in our financial health report.</li>
<li>Examine Waterdrop's earnings growth report to understand how analysts expect it to perform.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的財務健康報告中更深入地瞭解 Waterdrop 的潛力。</li>
<li>檢查 Waterdrop 的收益增長報告，以瞭解分析師對其表現的預期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5ec70547-526e-42d6-ac6d-8a4bcdf65c9f/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/5ec70547-526e-42d6-ac6d-8a4bcdf65c9f/chart/financial-position-analysis"/></p>
<p>WDH Financial Position Analysis as at Oct 2025</p>
<div class="lb-trans"><p>WDH 財務狀況分析截至 2025 年 10 月</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用機會</h2>
</div><ul>
<li>Get an in-depth perspective on all 362 US Penny Stocks by using our screener here.</li>
<li>Searching for a Fresh Perspective? The end of cancer? These 28 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過在這裏使用我們的篩選器，深入瞭解所有 362 只美國便士股票。</li>
<li>尋找新的視角？癌症的終結？這 28 只新興 AI 股票正在開發技術，以便早期識別改變生命的疾病，如癌症和阿爾茨海默病。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

Rapid Micro Biosystems 和兩個值得關注的有前景的便士股票